text:  In New York, where Trump has already been convicted for falsifying business records, prosecutors said today they would agree to delay his sentencing, which was set for July 11th. A new drug for patients with early Alzheimer's disease now has FDA approval. Clinical studies found that kasunla did not reverse, but rather slowed cognitive decline. The drug clears clumps of protein linked with Alzheimer's disease from the brain after MRI scans show the clumps are gone. The once-every-four-weeks infusion of kasunla can be stopped.